BYD Launched BAO 5 under Its New Brand FANGCHENGBAO and the DMO Technology
4.9.2023 12:43:00 EEST | Business Wire | Press release
BYD, the world’s leading manufacturer of new energy vehicles and power batteries, introduced FANGCHENGBAO, its new professional personalized sub-brand, as well as its sophisticated technology: the Dual Mode Off-road (DMO) Super Hybrid Platform. The first model of the new brand - BAO 5, a super hybrid off-road SUV harnessing the DMO technology was launched during the event as well as a concept car BAO 8 and BAO 3.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230817807422/en/
Wang Chuanfu, the Chairman and President of BYD (Photo: Business Wire)
Wang Chuanfu, the Chairman and President of BYD, said at the launch event that FANGCHENGBAO aspires to redefine vehicular experience by offering an unparalleled blend of professionalism and personalization to global users, driving a profound "revolution" in the NEV landscape, transforming cars into unique, tailor-made assets for every individual.
The Brand: A great leap in New Energy Vehicle Sector
The brand name FANGCHENGBAO, derived from Chinese phonetics, symbolizes a blend of precision ("FANGCHENG" for "formula") and agility ("BAO" for "leopard"), introducing a series of specialized technologies, including the DMO Super Hybrid Off-Road Platform, which is also inaugurated at the event.
FANGCHENGBAO envisions the confluence of state-of-the-art new energy technologies and diverse users' preferences will unlock unprecedented user experience: whether journeying through the vast wilderness, speeding on a racetrack, navigating through bustling cityscapes, or cruising on highways; whether seeking occasional exhilaration or traversing daily commutes, an exclusive driving experience for every scenario is now within reach.
To meet this end, FANGCHENGBAO will integrate BYD's apex technologies, forward-looking designing ethos, and the vertically integrated supply chain system, in order to enrich every vehicle with distinctive tailor-made possibilities.
FANGCHENGBAO symbolizes the fusion of new energy and boundless possibilities, turning every individual's dreams into tangible reality.
The DMO Technology: Unleashing the Might of Electricity for Individual Empowerment
At the event, BYD unveiled the innovative DMO Super Hybrid Off-Road Platform, signaling a significant pivot from traditional gasoline engines. This platform powers the FANGCHENGBAO vehicles, promising a transformative off-road experience while championing energy efficiency, and empowering every user with pinnacle technology.
The DMO combines BYD's Revolutionary Non-Load-Bearing Frame Designed for Hybrids with a specialized off-road hybrid architecture. This integration taps into BYD's expertise in high-performance chassis, intelligent electric four-wheel drive, and off-road powertrains. As a result, DMO strikes an unparalleled balance between vehicle safety, powerful off-roading, and energy consumption.
Instead of traditional modifications that add weight and increase rollover risks, the DMO innovatively fuses the Blade Battery and high-strength steel frame, evolving to the Cell to Chassis (CTC) technology. This not only ensures battery safety during extreme off-road scenarios but also significantly boosts overall vehicle safety.
The platform also boasts features like the longitudinal EHS electric hybrid system and an industry-first off-road rear-drive powertrain, as well as the Xiaoyun longitudinal high-performance engine, delivering a formidable system power of more than 500kW and an unmatched traction of 32,000N. Moreover, DMO vehicles utilize intelligent torque control technology to minimize the turning radius to just 3.4 meters. Also thanks to its powerful drive and precise electronic control, users can effortlessly navigate through swampy terrains, rugged mountains, gravelly slopes, and many other extreme terrains with the DMO. Equipped with three Differential Locks, drivers can switch to low-speed gear, which is designed for off-road scenario, with a push on the button.
Building on this innovative architecture, DMO incorporates a double-wishbone independent suspension at both ends, which, when paired with DiSus-P Hydraulic Body Control System, assures SUV-like comfort even in challenging terrains. The platform achieves 35% fuel savings compared to gasoline-powered off-road vehicles.
DMO stands out as a predominantly electric-driven, professional-grade off-road platform. It represents the culmination of over twenty years of BYD's cutting-edge technological evolution and insights from the experience gleaned from millions of BYD PHEVs. This platform transcends the conventional and substantially amplifies the capabilities of electric mobility. With its vast technical prowess, the DMO surmounts challenges that new energy vehicles typically encountered across scenarios, recalibrating the paradigm for off-road vehicular design and functionality.
Looking ahead, FANGCHENGBAO is set to venture into domains such as off-road SUVs and sports cars, where traditional gasoline vehicles predominate, starting from models with the DMO platform.
The New Models: Pioneers With Leading Technology and Unique Product Offerings
Three FANGCHENGBAO's models offer a powerful product lineup, catering to a range of individual preferences, demonstrating its robust product matrix and its dedication to professionalism and individuality.
The BAO 5, positioned as a super hybrid off-road SUV, is equipped with key technologies like DMO and DiSus-P Hydraulic body control system. Its design seamlessly combines industrial aesthetics with robust power, delivering unparalleled stability and safety for users.
As a brand emphasizing customization, FANGCHENGBAO offers the BAO 5 a variety of front-face structures that can be seamlessly integrated or adjusted. It provides a flexible foundation tailored to each user's unique modification preferences.
The BAO 8 concept car, named SUPER 8, unveils the brand's futuristic vision for off-road SUVs. Inspired by sci-fi battlefields, this design ensures robust integration and enhanced protection, inspiring driver confidence. Furthermore, preliminary details about the BAO 3 were revealed, hinting at a trendy model geared towards diverse audiences with a playful spirit.
To ensure consistent service and experience quality, FANGCHENGBAO will adopt a Direct-to-Consumer (DTC) model in the initial phase in the Chinese market, planning to reach 60 cities by 2024. It is also announced that the BAO 5 will have its first offline debut at the Chengdu Motor Show, starting August 25th.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230817807422/en/
Contact information
Asia-Pacific: Liya Huang, pr@byd.com tel: +86-755-8988-8888-69666
Europe: Penny Peng, PressEU@byd.com tel: +31-102070888
North America: Frank Girardot, frank.girardot@byd.com tel: +1 213 245 6503
Latin America: José Miranda, jose.miranda@byd.com
tel: +56 9 96443906
Brazil: Pablo Toledo, pablo.toledo@byd.com tel: +19 3514 2554
Middle East and Africa: Nikki Li, li.namin@byd.com tel: +86-18938862670
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
